Vitamin D: excess and interactions

How to account for total vitamin D intake, recognise signs of excess and check combinations with medicines.

Key points

  • For adults, the US upper limit is 4,000 IU vitamin D daily from food and supplements combined. This is a limit, not an intake target. [1] See the evidence 1 2
  • Excess vitamin D can raise blood calcium and cause nausea, weakness or thirst. Check the amount of vitamin D in all products you take. [1] See the evidence 1 2

Practical guide

Please double-check the conclusions and consider your own circumstances when choosing a supplement.

When taking vitamin D, consider all sources and medicines. Safety also depends on health conditions and total calcium intake.

Amount and signs of excess

Why these conclusions

Excess vitamin D and calcium

Elevated calcium from excess vitamin D may be accompanied by vomiting, frequent urination and kidney stones. Severe toxicity can damage the kidneys and cause arrhythmia. If you have nausea, vomiting, weakness, extreme thirst or frequent urination, seek medical assessment and show the ingredients and doses of all products. These symptoms alone do not establish the cause. [1]

In a three-year study of healthy adults aged 55–70 assigned 400, 4,000 or 10,000 IU D3 daily, at least one episode of elevated blood calcium was found in 0 of 124, 4 of 125 and 11 of 124 people, respectively. All episodes were mild and resolved on repeat testing; some participants reduced calcium intake before that test. [2]

Elevated urinary calcium was found at least once in 21 of 124, 28 of 125 and 38 of 124 participants in these three groups, respectively. These were laboratory episodes, not the frequency of kidney failure. [2] [1]

In the study, participants with low dietary calcium received an additional 300 or 600 mg elemental calcium daily. In the group assigned 10,000 IU, D3 content declined in two batches and, after months 18–24, the actual daily dose until study end was estimated at 2,000–10,000 IU. [2] [3]

In a seven-year study of postmenopausal women, 1,000 mg calcium and 400 IU vitamin D daily increased the relative risk of kidney stones by 17% versus placebo in the setting of high total calcium intake. [1]

Vitamin D aids calcium absorption; calcium needs are assessed separately based on the whole diet. The supplied sources do not establish that every buyer must take D with magnesium or K2.

ParameterData
ResultVitamin D aids calcium absorption; calcium needs are assessed separately based on the whole diet. The supplied sources do not establish that every buyer must take D with magnesium or K2.
ParticipantsPeople considering D, magnesium, K2 and calcium supplements
Formvitamin D and calcium; magnesium and K2 as possible products
DoseNo universal combination dose established
Dose basistotal dietary calcium intake
ComparisonNot applicable: a descriptive fact or an organisation’s recommendation, not a comparison of study groups.
DurationNot applicable: the source describes a fact or standard, not an observation over a fixed period.
ConfidenceA descriptive fact, summary of an official recommendation or rule; the effectiveness rating scale does not apply.
Volume of evidenceNamed sources: 1
Sources[1]

Check the composition of all products you take to account for total vitamin D; the specific schedule for combining supplements depends on ingredients and medicines.

ParameterData
ResultCheck the composition of all products you take to account for total vitamin D; the specific schedule for combining supplements depends on ingredients and medicines.
ParticipantsPeople taking several supplements
Formproducts containing D3 or other vitamin D
Dosesum of amounts in the servings used
Dose basisall products taken and their labelled servings
ComparisonNot applicable: a descriptive fact or an organisation’s recommendation, not a comparison of study groups.
DurationNot applicable: the source describes a fact or standard, not an observation over a fixed period.
ConfidenceA descriptive fact, summary of an official recommendation or rule; the effectiveness rating scale does not apply.
Volume of evidenceNamed sources: 1
Sources[1]

In a seven-year study of postmenopausal women, 1,000 mg calcium plus 400 IU vitamin D daily increased kidney stone risk by 17% relative to placebo in the setting of high total calcium intake.

ParameterData
Resultrelative risk increase 17%; absolute risk was not reported in the captured excerpt
Participants36,282 postmenopausal women in a randomised study
FormCalcium and vitamin D supplements; the specific chemical form was not specified in the captured NIH excerpt
Dose1,000 mg calcium + 10 µg (400 IU) vitamin D daily
Dose basisassigned supplements daily; total intake includes food and supplements
Comparisonplacebo
Duration7 years
Confidence2/4: One large randomised study in a postmenopausal population with high total calcium intake; the source does not establish the effect of vitamin D separately from calcium; absolute risk and the interval around the estimate are absent from the captured excerpt.
Volume of evidenceNamed sources: 1
Sources[1]

Excess vitamin D can raise blood calcium: nausea, vomiting, weakness, thirst, frequent urination and kidney stones may occur; severe toxicity can damage the kidneys and cause arrhythmia.

ParameterData
ResultExcess vitamin D can raise blood calcium: nausea, vomiting, weakness, thirst, frequent urination and kidney stones may occur; severe toxicity can damage the kidneys and cause arrhythmia.
ParticipantsPeople with toxic vitamin D excess
Formvitamin D, mainly from supplements
DoseNo fixed toxic dose; signs depend on the excess
Dose basiselevated blood and urinary calcium
ComparisonNot applicable: a descriptive fact or an organisation’s recommendation, not a comparison of study groups.
DurationNot applicable: the source describes a fact or standard, not an observation over a fixed period.
ConfidenceA descriptive fact, summary of an official recommendation or rule; the effectiveness rating scale does not apply.
Volume of evidenceNamed sources: 1
Sources[1]

For adults, the FNB specifies an upper limit of 100 µg (4,000 IU) daily from food and supplements—this is a limit, not a target dose.

ParameterData
ResultFor adults, the FNB specifies an upper limit of 100 µg (4,000 IU) daily from food and supplements—this is a limit, not a target dose.
ParticipantsAdults aged 19 and over
Formvitamin D from food and supplements
DoseUL 100 µg (4,000 IU)/day
Dose basistotal daily intake
ComparisonNot applicable: a descriptive fact or an organisation’s recommendation, not a comparison of study groups.
DurationNot applicable: the source describes a fact or standard, not an observation over a fixed period.
ConfidenceA descriptive fact, summary of an official recommendation or rule; the effectiveness rating scale does not apply.
Volume of evidenceNamed sources: 1
Sources[1]

If you have high calcium, kidney disease or hyperparathyroidism, discuss vitamin D and all medicines with a doctor. Vitamin D increases calcium absorption and with thiazide diuretics may cause hypercalcaemia, especially with impaired kidney function and hyperparathyroidism.

ParameterData
ResultIf you have high calcium, kidney disease or hyperparathyroidism, discuss vitamin D and all medicines with a doctor. Vitamin D increases calcium absorption and with thiazide diuretics may cause hypercalcaemia, especially with impaired kidney function and hyperparathyroidism.
ParticipantsPeople with high calcium, impaired kidney function or hyperparathyroidism; increased risk on thiazides
Formvitamin D and a thiazide diuretic
DoseNo specific dose stated in the source
Dose basiscombination of supplement and medicine
ComparisonNot applicable: a descriptive fact or an organisation’s recommendation, not a comparison of study groups.
DurationNot applicable: the source describes a fact or standard, not an observation over a fixed period.
ConfidenceA descriptive fact, summary of an official recommendation or rule; the effectiveness rating scale does not apply.
Volume of evidenceNamed sources: 1
Sources[1]

Orlistat with a reduced-fat diet can reduce vitamin D absorption. Corticosteroids can reduce calcium absorption and disrupt vitamin D metabolism; thiazides with vitamin D can raise blood calcium. High vitamin D doses may also reduce the effect of some statins; discuss all medicines and supplements with a doctor.

ParameterData
ResultOrlistat with a reduced-fat diet can reduce vitamin D absorption. Corticosteroids can reduce calcium absorption and disrupt vitamin D metabolism; thiazides with vitamin D can raise blood calcium. High vitamin D doses may also reduce the effect of some statins; discuss all medicines and supplements with a doctor.
ParticipantsPeople taking orlistat, corticosteroids, thiazides or some statins
Formoral vitamin D and the relevant medicine
DoseDoses not stated; high vitamin D intake is mentioned for statins
Dose basisspecific combination; medicines do not all behave identically
ComparisonNot applicable: a descriptive fact or an organisation’s recommendation, not a comparison of study groups.
DurationNot applicable: the source describes a fact or standard, not an observation over a fixed period.
ConfidenceA descriptive fact, summary of an official recommendation or rule; the effectiveness rating scale does not apply.
Volume of evidenceNamed sources: 1
Sources[1]

Nausea, vomiting, weakness, extreme thirst and frequent urination may accompany elevated calcium caused by excess vitamin D. Seek medical assessment for these symptoms and show the ingredients and doses of all products taken: symptoms alone do not establish the cause.

ParameterData
ResultNausea, vomiting, weakness, extreme thirst and frequent urination may accompany elevated calcium caused by excess vitamin D. Seek medical assessment for these symptoms and show the ingredients and doses of all products taken: symptoms alone do not establish the cause.
ParticipantsPeople with the listed symptoms taking several supplements
Formvitamin D and other supplements
DoseDose not established; ingredients and doses need checking
Dose basissymptoms and potential excess; causation not established
ComparisonNot applicable: a descriptive fact or an organisation’s recommendation, not a comparison of study groups.
DurationNot applicable: the source describes a fact or standard, not an observation over a fixed period.
ConfidenceA descriptive fact, summary of an official recommendation or rule; the effectiveness rating scale does not apply.
Volume of evidenceNamed sources: 1
Sources[1]

In a three-year study in adults aged 55–70, at least one laboratory episode of hypercalcaemia was found in 0 of 124, 4 of 125 and 11 of 124 participants assigned 400, 4,000 and 10,000 IU D3 daily, respectively. All episodes were mild and resolved on repeat testing; some participants reduced calcium intake before that test.

ParameterData
ResultIn a three-year study in adults aged 55–70, at least one laboratory episode of hypercalcaemia was found in 0 of 124, 4 of 125 and 11 of 124 participants assigned 400, 4,000 and 10,000 IU D3 daily, respectively. All episodes were mild and resolved on repeat testing; some participants reduced calcium intake before that test.
Participants373 healthy men and postmenopausal women aged 55–70 in the Calgary area. Baseline 25(OH)D 30–125 nmol/L, bone density T-score above −2.5. Participants with abnormal baseline blood calcium, recent supplement use over 2,000 IU/day, bone-active medication or vitamin D metabolism disorders were excluded. All 373 received at least one dose.
FormLiquid oral cholecalciferol D3, Ddrops
DoseAssigned 400, 4,000 or 10,000 IU daily
Dose basisIU of D3 activity in the study supplement per day. Five drops daily contained the assigned 80, 800 or 2,000 IU per drop. Dietary vitamin D was counted separately; up to 200 IU/day outside the study was permitted.
ComparisonOther randomised active-dose groups; reference 400 IU/day, no placebo
Duration3 years
Confidencelow: The blinded randomised study directly measured laboratory markers. Confidence was downgraded one level because the actual dose in the 10,000 IU group was uncertain after content fell in two batches between months 18 and 24; through month 36 the dose was estimated at 2,000–10,000 IU/day. Another downgrade reflects imprecision of the comparative estimate: 15 people had hypercalcaemia and no verified pairwise interval is available. A single study or diagnosis alone was not a reason for downgrading.
Volume of evidence1
Sources[2]

In the same study, laboratory hypercalciuria was found at least once in 21 of 124, 28 of 125 and 38 of 124 participants assigned 400, 4,000 and 10,000 IU D3 daily, respectively; approximately 17%, 22% and 31%. This is a urinary calcium measure, not kidney failure frequency.

ParameterData
ResultIn the same study, laboratory hypercalciuria was found at least once in 21 of 124, 28 of 125 and 38 of 124 participants assigned 400, 4,000 and 10,000 IU D3 daily, respectively; approximately 17%, 22% and 31%. This is a urinary calcium measure, not kidney failure frequency.
Participants373 healthy men and postmenopausal women aged 55–70 in the Calgary area. Baseline 25(OH)D 30–125 nmol/L, bone density T-score above −2.5. Participants with abnormal baseline blood calcium, recent supplement use over 2,000 IU/day, bone-active medication or vitamin D metabolism disorders were excluded. All 373 received at least one dose.
FormLiquid oral cholecalciferol D3, Ddrops
DoseAssigned 400, 4,000 or 10,000 IU daily
Dose basisIU of D3 activity in the study supplement per day. Five drops daily contained the assigned 80, 800 or 2,000 IU per drop. Dietary vitamin D was counted separately; up to 200 IU/day outside the study was permitted.
ComparisonOther randomised active-dose groups; reference 400 IU/day, no placebo
Duration3 years
Confidencemoderate: The blinded randomised study prespecified and repeatedly measured the urinary outcome; 87 participants had an episode, dose trend p=0.01. Confidence was downgraded one level because product content fell in the high-dose group. There was no additional downgrade for imprecision of the presence of a trend or inconsistency in a single study; pairwise precision is not established.
Volume of evidence1
Sources[2]

The US FNB sets an upper limit for adults of 4,000 IU (100 µg) vitamin D daily from food, drinks and supplements. This is not a target dose, toxicity threshold or guarantee of individual safety.

ParameterData
ResultThe US FNB sets an upper limit for adults of 4,000 IU (100 µg) vitamin D daily from food, drinks and supplements. This is not a target dose, toxicity threshold or guarantee of individual safety.
ParticipantsAdults in the US
FormVitamin D from food, drinks and supplements
Dose4,000 IU (100 µg) daily
Dose basisTotal intake from all food sources and supplements
ComparisonOfficial standard, not a comparative study
DurationDaily reference
Confidencenot applicable: An official standard, source-described safety or interaction fact, or study-method context. An effectiveness rating does not apply.
Volume of evidenceNamed sources: 1
Sources[1]

Excess vitamin D, usually associated with excessive supplement intake, can raise blood and urinary calcium. Hypercalcaemia may be accompanied by nausea, weakness, thirst, frequent urination and stones; extremely severe toxicity can cause kidney failure.

ParameterData
ResultExcess vitamin D, usually associated with excessive supplement intake, can raise blood and urinary calcium. Hypercalcaemia may be accompanied by nausea, weakness, thirst, frequent urination and stones; extremely severe toxicity can cause kidney failure.
ParticipantsPeople with excessive vitamin D intake
FormVitamin D supplements
DoseNo single toxic dose established
Dose basisTotal intake and individual circumstances
ComparisonSafety description, not a comparative study
DurationTime to onset not established
Confidencenot applicable: An official standard, source-described safety or interaction fact, or study-method context. An effectiveness rating does not apply.
Volume of evidenceNamed sources: 1
Sources[1]

In the study, participants with low dietary calcium received an additional 300 or 600 mg elemental calcium daily, aiming for approximately 1,200 mg total intake; 263 people started the supplement at randomisation. Of 15 participants with hypercalcaemia, 10 were taking calcium at that time; results relate to this protocol.

ParameterData
ResultIn the study, participants with low dietary calcium received an additional 300 or 600 mg elemental calcium daily, aiming for approximately 1,200 mg total intake; 263 people started the supplement at randomisation. Of 15 participants with hypercalcaemia, 10 were taking calcium at that time; results relate to this protocol.
Participants373 healthy men and postmenopausal women aged 55–70 in the Calgary area. Baseline 25(OH)D 30–125 nmol/L, bone density T-score above −2.5. Participants with abnormal baseline blood calcium, recent supplement use over 2,000 IU/day, bone-active medication or vitamin D metabolism disorders were excluded. All 373 received at least one dose.
FormOral elemental calcium with D3
Dose300 or 600 mg elemental calcium daily as needed
Dose basisMass of elemental calcium; target total intake includes food
ComparisonCalcium assigned according to dietary need in each D3 group
DurationUp to 3 years; calcium intake could change
Confidencenot applicable: An official standard, source-described safety or interaction fact, or study-method context. An effectiveness rating does not apply.
Volume of evidenceNamed sources: 1
Sources[2]

Participants were assigned 400, 4,000 or 10,000 IU D3 daily; no more than an additional 200 IU daily was allowed. In the 10,000 IU group, content in two batches declined between months 18 and 24, and through month 36 the actual dose was estimated at 2,000–10,000 IU daily.

ParameterData
ResultParticipants were assigned 400, 4,000 or 10,000 IU D3 daily; no more than an additional 200 IU daily was allowed. In the 10,000 IU group, content in two batches declined between months 18 and 24, and through month 36 the actual dose was estimated at 2,000–10,000 IU daily.
Participants373 healthy men and postmenopausal women aged 55–70 in the Calgary area. Baseline 25(OH)D 30–125 nmol/L, bone density T-score above −2.5. Participants with abnormal baseline blood calcium, recent supplement use over 2,000 IU/day, bone-active medication or vitamin D metabolism disorders were excluded. All 373 received at least one dose.
FormLiquid oral cholecalciferol D3, Ddrops
DoseAssigned 400, 4,000 or 10,000 IU daily
Dose basisIU of D3 activity in the study supplement per day. Five drops daily contained the assigned 80, 800 or 2,000 IU per drop. Dietary vitamin D was counted separately; up to 200 IU/day outside the study was permitted.
ComparisonOther randomised active-dose groups; reference 400 IU/day, no placebo
Duration3 years
Confidencenot applicable: An official standard, source-described safety or interaction fact, or study-method context. An effectiveness rating does not apply.
Volume of evidenceNamed sources: 2
Sources[2] [3]

Thiazide diuretics reduce urinary calcium excretion; combining them with vitamin D may cause hypercalcaemia, especially in older people and those with impaired kidney function or hyperparathyroidism. A numerical frequency for this interaction is not established here.

ParameterData
ResultThiazide diuretics reduce urinary calcium excretion; combining them with vitamin D may cause hypercalcaemia, especially in older people and those with impaired kidney function or hyperparathyroidism. A numerical frequency for this interaction is not established here.
ParticipantsPeople taking thiazide diuretics, especially older people and those with impaired kidney function or hyperparathyroidism
FormVitamin D supplements and thiazide diuretics
DoseNo dose threshold stated for the interaction
Dose basisQualitative description of interaction
ComparisonNot applicable to a description of interaction
DurationWith concurrent use; exact time not stated
Confidencenot applicable: An official standard, source-described safety or interaction fact, or study-method context. An effectiveness rating does not apply.
Volume of evidenceNamed sources: 1
Sources[1]

Orlistat combined with a reduced-fat diet can reduce absorption of vitamin D from food and supplements and lower 25(OH)D. This is a separate interaction, not a subgroup result from the Calgary study.

ParameterData
ResultOrlistat combined with a reduced-fat diet can reduce absorption of vitamin D from food and supplements and lower 25(OH)D. This is a separate interaction, not a subgroup result from the Calgary study.
ParticipantsPeople taking orlistat on a reduced-fat diet
FormVitamin D from food and supplements
DoseNo dose threshold stated for the interaction
Dose basisQualitative description of interaction
ComparisonNot applicable to a description of interaction
DurationWith concurrent use; exact time not stated
Confidencenot applicable: An official standard, source-described safety or interaction fact, or study-method context. An effectiveness rating does not apply.
Volume of evidenceNamed sources: 1
Sources[1]

The Calgary study percentages refer to laboratory episodes of hypercalcaemia and hypercalciuria in selected participants, not the frequency of kidney failure. These results do not establish equal safety in chronic kidney disease, in all people with stones, or with uncontrolled supplement use.

ParameterData
ResultThe Calgary study percentages refer to laboratory episodes of hypercalcaemia and hypercalciuria in selected participants, not the frequency of kidney failure. These results do not establish equal safety in chronic kidney disease, in all people with stones, or with uncontrolled supplement use.
Participants373 healthy men and postmenopausal women aged 55–70 in the Calgary area. Baseline 25(OH)D 30–125 nmol/L, bone density T-score above −2.5. Participants with abnormal baseline blood calcium, recent supplement use over 2,000 IU/day, bone-active medication or vitamin D metabolism disorders were excluded. All 373 received at least one dose.
FormLiquid oral cholecalciferol D3, Ddrops
DoseAssigned 400, 4,000 or 10,000 IU daily
Dose basisIU of D3 activity in the study supplement per day. Five drops daily contained the assigned 80, 800 or 2,000 IU per drop. Dietary vitamin D was counted separately; up to 200 IU/day outside the study was permitted.
ComparisonOther randomised active-dose groups; reference 400 IU/day, no placebo
Duration3 years
Confidencenot applicable: An official standard, source-described safety or interaction fact, or study-method context. An effectiveness rating does not apply.
Volume of evidenceNamed sources: 2
Sources[2] [1]

Drug interactions

MedicineInteractionWhat to considerSources
Thiazide diuretics, for example hydrochlorothiazideCombining with vitamin D can raise blood calcium; risk is higher in older people and those with impaired kidney function or hyperparathyroidism.Before starting a supplement, discuss its dose with a doctor; if you have impaired kidney function or hyperparathyroidism, or are older, ask whether blood calcium monitoring is needed.[1] [4]
Orlistat, for example XenicalOrlistat with a reduced-fat diet can reduce absorption of vitamin D from food and supplements. 25(OH)D levels may fall.The FDA label for Xenical says to take a multivitamin containing fat-soluble vitamins at least 2 hours before or 2 hours after Xenical, or at bedtime; check your own medicine’s instructions.[1] [5]
Systemic corticosteroids, for example prednisoneSystemic corticosteroids can reduce calcium absorption and disrupt vitamin D metabolism; long-term use is also associated with bone loss.With long-term use, discuss calcium and vitamin D intake, bone loss risk and the need for bone density testing with a doctor.[1] [6]
Some statins: atorvastatin, lovastatin, simvastatinHigh vitamin D intake, especially from supplements, may reduce the effect of these statins; NIH notes a possible interaction.Before starting or increasing a supplement dose, show its ingredients and vitamin D amount to a doctor or pharmacist and check compatibility with the specific statin.[1] [4]

More details

Combining supplements and medicines

Vitamin D helps calcium absorption, and calcium needs are assessed using the total diet. A requirement for everyone to combine vitamin D with magnesium or K2 has not been established. [1]

If you have high calcium, kidney disease or hyperparathyroidism, discuss vitamin D and all medicines with a doctor. Thiazide diuretics with vitamin D can raise blood calcium, particularly in older people and those with impaired kidney function or hyperparathyroidism. [1]

Orlistat with a reduced-fat diet may reduce vitamin D absorption. Corticosteroids can reduce calcium absorption and disrupt vitamin D metabolism, and high D doses may reduce the effect of some statins. [1]

The FDA label for Xenical says to take a multivitamin containing fat-soluble vitamins at least two hours before the medicine, two hours after it or at bedtime. Check your own medicine’s instructions. [1] [4] [5] [6]

Sources

  1. Vitamin D - Health Professional Fact Sheet. https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/
  2. Safety of High-Dose Vitamin D Supplementation: Secondary Analysis of a Randomized Controlled Trial. https://academic.oup.com/jcem/article/105/4/1261/5634116
  3. Corrigendum to: “Safety of High-Dose Vitamin D Supplementation: Secondary Analysis of a Randomized Controlled Trial”. https://academic.oup.com/jcem/article/106/4/e1932/6095394
  4. Vitamin D - Consumer Fact Sheet. https://ods.od.nih.gov/factsheets/VITAMIND-Consumer/
  5. XENICAL (orlistat) capsules, prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/020766s039lbl.pdf
  6. Osteoporosis Inducida por Glucocorticoides. https://rheumatology.org/patients/osteoporosis-inducida-por-glucocorticoides

Methodology: Subpages evidence-led supplement pipeline v1

Ingredient overview: Vitamin D